Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
20.60
-0.50 (-2.37%)
Mar 3, 2026, 5:35 PM CET
Market Cap829.44M +11.3%
Revenue (ttm)84.66M +2,060.3%
Net Income45.91M
EPS1.14
Shares Out40.26M
PE Ratio18.03
Forward PE5.25
Dividendn/a
Ex-Dividend Daten/a
Volume25,227
Average Volume11,791
Open21.00
Previous Close21.10
Day's Range20.60 - 21.60
52-Week Range17.80 - 27.80
Beta0.09
RSI50.97
Earnings DateMar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 201
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements